Lantheus (LNTH) Expected to Post Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Lantheus to post earnings of $1.24 per share and revenue of $360.07 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same quarter last year, the company earned $1.57 earnings per share. Lantheus’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, analysts expect Lantheus to post $4.54 EPS for the current fiscal year and $5.61 EPS for the next fiscal year.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded up $0.19 on Tuesday, reaching $100.50. 95,683 shares of the company were exchanged, compared to its average volume of 1,078,672. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. Lantheus has a 1-year low of $50.15 and a 1-year high of $111.86. The firm has a market cap of $6.56 billion, a price-to-earnings ratio of 24.28 and a beta of -0.06. The company has a 50-day moving average of $100.27 and a 200-day moving average of $91.34.

Analyst Upgrades and Downgrades

Several analysts recently commented on LNTH shares. Brookline Capital Markets cut shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and lowered their target price for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Mizuho lowered Lantheus from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $115.00 to $109.00 in a report on Tuesday, October 13th. B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. Finally, Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and cut their price target for the stock from $125.00 to $102.50 in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $107.44.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.